Hepatopancreatic dysfunction in patients with metabolic syndrome by Zhuravlyova, Larysa et al.
HEPATOPANCREATIС DYSFUNCTION IN PATIENTS WITH METABOLIC SYNDROME
L.Zhuravlyova, T.Moiseenko, Y.Shekhovtsova.
Kharkiv National Medical University
 Insulin resistance (IR) is a basic defect in patients with metabolic syndrome (MS), which determines numerous  multiorgan complications. 
Objective:
To study the influence of the liver and pancreas on the course of MS and hormone-metabolic status of patients. 
Methods:
32 patients with grade 1 obesity (BMI 32,2 ± 2,1 kg/m2) with signs of MS according to IDF (2007) criteria, and grade 1-2 arterial hypertension (group 1) were examined and 10 individuals of the control group. All patients were middle-aged men (45-59 years). The survey plan included: echosonography of abdominal and retroperitoneal space, coprogram, determination of elastase-1 in feces, C-reactive protein(CRP), cholesterol, HDL, LDL, VLDL , triglycerides, free fatty acids (FFA), malonic dialdehyde (MDA), indicators of hormonal balance (insulin, the rate of HOMA-IR, cortisol, growth hormone, TSH, prolactin), cytokines (interleukin-6, tumor necrosis factor-α).
Results:
The presence of clinical markers of IR was accompanied by a significant increase in HOMA-IR, sonographic signs of nonalcoholic hepatic steatosis. In these patients, sonography has determined  increase of the pancreas size, predominantly the tail, and increased echogenicity of the pancreas. The changes of coprogram were detected in 52.6% of patients with MS. The content of elastase-1 in feces of patients was significantly reduced in relation to control (180,7 ± 16,2 mg / g, p <0,05). The constellation of hepatic and pancreatic damage in such patients was described as a phenomenon of hepatopancreatic dysfunction (HPD). HPD was accompanied by a lack of antiatherogenic lipid fractions (HDL) and the accumulation of atherogenic fractions (LDL, VLDL and FFA). IR revealed itself against a background of pronounced hormonal imbalance: hyperсortisolemia, increase in TSH, higher levels of prolactin and decline of growth hormone levels. Hyperdyslipidemia in patients with MS was accompanied by increased levels of MDA. HPD was accompanied by increased levels of proinflammatory cytokines in the blood, as well as tumor necrosis factor-α and interleukin-6, CRP and fibrinogen.
Conclusions:
Hepatic steatosis and pancreatic steatosis accompany MS with grade 1 obesity. HPD is accompanied by the presence of atherogenic hyperdyslipidemia, increased levels of proinflammatory cytokines, activation of lipid peroxidation and disorders of hormone-metabolic status: increase of the rate of HOMA-IR, the phenomenon of activation of the adrenal cortex with hypercortisolemia, the phenomenon of subclinical hypothyroidism with elevated TSH, the phenomenon of premature ageing of the pituitary gland with increased prolactin levels and decreased levels of growth hormone.

